Your session is about to expire
← Back to Search
Drug Combinations for Bacterial Pneumonia (REITAB-2 Trial)
REITAB-2 Trial Summary
This trialwill compare two drugs to treat hospital- or ventilator-acquired pneumonia in adults.
REITAB-2 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowREITAB-2 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.REITAB-2 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are expected to live for less than 3 days.I have been treated with antibiotics for a lung infection for more than 24 hours in the last 3 days.You have abnormal test results in your blood samples taken before the study starts.I have a lung infection needing IV antibiotics, starting after hospital stay or ventilation.I am currently on or have been on seizure medication in the past 3 years.I have symptoms like coughing, difficulty breathing, or fever.You had a severe allergic reaction to beta-lactam antibiotics or any ingredients in the study drug.You have high levels of white blood cells or immature neutrophils in your laboratory tests.I have a lung infection due to blockage, possibly from lung cancer.I am in a severe, unresponsive state of septic shock.Your APACHE II score is higher than 30.My kidney function is very low.The test of your respiratory sample only shows a certain type of bacteria called Gram-positive cocci.You have new or worsening signs of bacterial pneumonia in your chest X-ray or CT scan.I am currently on dialysis.I am not pregnant, breastfeeding, or have a positive pregnancy test.You have a documented weak immune system or immune system condition.I have an infection in my brain or spinal cord.I am expected to be treated with specific medications for a lung infection.I have a history of liver disease or cirrhosis.I am willing to use birth control during and after the study.I have or might have pneumonia, including from COVID-19 or chemicals.
- Group 1: Imipenem/Cilastatin/Relebactam
- Group 2: Imipenem/Cilastatin/XNW4107
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are partaking in this clinical experiment?
"This medical trial requires 450 eligible individuals to enroll, and multiple sites have opened for enrollment such as Jackson Memorial Hospital (JMH) - Ryder Trauma Center in Miami, Florida and USF-TGH in Tampa, Maryland."
Has the Imipenem/Cilastatin/XNW4107 combination been given regulatory clearance by the FDA?
"Our analysts at Power assign a safety score of 3 to Imipenem/Cilastatin/XNW4107 due to the Phase 3 trial process, wherein there exists evidence for efficacy and multiple instances of data corroborating its security."
How widely is this experiment being implemented?
"The current roster of clinical sites active in this trial includes Jackson Memorial Hospital (JMH) - Ryder Trauma Center in Miami, USF-TGH in Tampa, and University of Maryland Medical Center in Baltimore; 6 other locations are also participating."
Does this research endeavor currently seek participants?
"Affirmative. The clinicaltrials.gov database states that this medical trial, originally launched on July 31st 2022, is currently recruiting for participants. It seeks 450 individuals to be enrolled across 9 different sites."
Share this study with friends
Copy Link
Messenger